Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review Article Swipe
Charlotte Beaudart
,
Christian Brabant
,
Majed S. Alokail
,
Jean-Yves Reginster
,
Olivier Bruyère
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40265-025-02234-5
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40265-025-02234-5
Related Topics
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1007/s40265-025-02234-5
- https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdf
- OA Status
- hybrid
- References
- 43
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4414012566
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414012566Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s40265-025-02234-5Digital Object Identifier
- Title
-
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella ReviewWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-05Full publication date if available
- Authors
-
Charlotte Beaudart, Christian Brabant, Majed S. Alokail, Jean-Yves Reginster, Olivier BruyèreList of authors in order
- Landing page
-
https://doi.org/10.1007/s40265-025-02234-5Publisher landing page
- PDF URL
-
https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdfDirect OA link when available
- Concepts
-
Medicine, Celecoxib, Pharmacotherapy, Intensive care medicine, Pharmacology, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
43Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4414012566 |
|---|---|
| doi | https://doi.org/10.1007/s40265-025-02234-5 |
| ids.doi | https://doi.org/10.1007/s40265-025-02234-5 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40911151 |
| ids.openalex | https://openalex.org/W4414012566 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000009 |
| mesh[1].descriptor_ui | D000068579 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | adverse effects |
| mesh[1].descriptor_name | Celecoxib |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D000068579 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Celecoxib |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D009140 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Musculoskeletal Diseases |
| mesh[4].qualifier_ui | Q000009 |
| mesh[4].descriptor_ui | D000894 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | adverse effects |
| mesh[4].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D000894 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D016032 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D002908 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Chronic Disease |
| mesh[8].qualifier_ui | Q000009 |
| mesh[8].descriptor_ui | D052246 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | adverse effects |
| mesh[8].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D052246 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D010003 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Osteoarthritis |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D015201 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Meta-Analysis as Topic |
| mesh[12].qualifier_ui | Q000188 |
| mesh[12].descriptor_ui | D001172 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | drug therapy |
| mesh[12].descriptor_name | Arthritis, Rheumatoid |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | Q000009 |
| mesh[14].descriptor_ui | D000068579 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | adverse effects |
| mesh[14].descriptor_name | Celecoxib |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000068579 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Celecoxib |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D009140 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Musculoskeletal Diseases |
| mesh[17].qualifier_ui | Q000009 |
| mesh[17].descriptor_ui | D000894 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | adverse effects |
| mesh[17].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D000894 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D016032 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D002908 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Chronic Disease |
| mesh[21].qualifier_ui | Q000009 |
| mesh[21].descriptor_ui | D052246 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | adverse effects |
| mesh[21].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D052246 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D010003 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Osteoarthritis |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D015201 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Meta-Analysis as Topic |
| mesh[25].qualifier_ui | Q000188 |
| mesh[25].descriptor_ui | D001172 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | drug therapy |
| mesh[25].descriptor_name | Arthritis, Rheumatoid |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D006801 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Humans |
| mesh[27].qualifier_ui | Q000009 |
| mesh[27].descriptor_ui | D000068579 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | adverse effects |
| mesh[27].descriptor_name | Celecoxib |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000068579 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Celecoxib |
| mesh[29].qualifier_ui | Q000188 |
| mesh[29].descriptor_ui | D009140 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | drug therapy |
| mesh[29].descriptor_name | Musculoskeletal Diseases |
| mesh[30].qualifier_ui | Q000009 |
| mesh[30].descriptor_ui | D000894 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | adverse effects |
| mesh[30].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[31].qualifier_ui | Q000627 |
| mesh[31].descriptor_ui | D000894 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | therapeutic use |
| mesh[31].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D016032 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D002908 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Chronic Disease |
| mesh[34].qualifier_ui | Q000009 |
| mesh[34].descriptor_ui | D052246 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | adverse effects |
| mesh[34].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D052246 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[36].qualifier_ui | Q000188 |
| mesh[36].descriptor_ui | D010003 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | drug therapy |
| mesh[36].descriptor_name | Osteoarthritis |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D015201 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Meta-Analysis as Topic |
| mesh[38].qualifier_ui | Q000188 |
| mesh[38].descriptor_ui | D001172 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | drug therapy |
| mesh[38].descriptor_name | Arthritis, Rheumatoid |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D006801 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Humans |
| mesh[40].qualifier_ui | Q000009 |
| mesh[40].descriptor_ui | D000068579 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | adverse effects |
| mesh[40].descriptor_name | Celecoxib |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D000068579 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Celecoxib |
| mesh[42].qualifier_ui | Q000188 |
| mesh[42].descriptor_ui | D009140 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | drug therapy |
| mesh[42].descriptor_name | Musculoskeletal Diseases |
| mesh[43].qualifier_ui | Q000009 |
| mesh[43].descriptor_ui | D000894 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | adverse effects |
| mesh[43].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[44].qualifier_ui | Q000627 |
| mesh[44].descriptor_ui | D000894 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | therapeutic use |
| mesh[44].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D016032 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D002908 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Chronic Disease |
| mesh[47].qualifier_ui | Q000009 |
| mesh[47].descriptor_ui | D052246 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | adverse effects |
| mesh[47].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[48].qualifier_ui | Q000627 |
| mesh[48].descriptor_ui | D052246 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | therapeutic use |
| mesh[48].descriptor_name | Cyclooxygenase 2 Inhibitors |
| mesh[49].qualifier_ui | Q000188 |
| mesh[49].descriptor_ui | D010003 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | drug therapy |
| mesh[49].descriptor_name | Osteoarthritis |
| type | review |
| title | Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review |
| biblio.issue | 10 |
| biblio.volume | 85 |
| biblio.last_page | 1306 |
| biblio.first_page | 1289 |
| topics[0].id | https://openalex.org/T10678 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2736 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Inflammatory mediators and NSAID effects |
| topics[1].id | https://openalex.org/T13489 |
| topics[1].field.id | https://openalex.org/fields/16 |
| topics[1].field.display_name | Chemistry |
| topics[1].score | 0.9818999767303467 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1605 |
| topics[1].subfield.display_name | Organic Chemistry |
| topics[1].display_name | Synthesis of β-Lactam Compounds |
| topics[2].id | https://openalex.org/T10814 |
| topics[2].field.id | https://openalex.org/fields/28 |
| topics[2].field.display_name | Neuroscience |
| topics[2].score | 0.9664000272750854 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2804 |
| topics[2].subfield.display_name | Cellular and Molecular Neuroscience |
| topics[2].display_name | Neuropeptides and Animal Physiology |
| is_xpac | False |
| apc_list.value | 3990 |
| apc_list.currency | EUR |
| apc_list.value_usd | 5290 |
| apc_paid.value | 3990 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 5290 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9131555557250977 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2776467144 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7418601512908936 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q408801 |
| concepts[1].display_name | Celecoxib |
| concepts[2].id | https://openalex.org/C500440147 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5742791295051575 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q701216 |
| concepts[2].display_name | Pharmacotherapy |
| concepts[3].id | https://openalex.org/C177713679 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5610045790672302 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[3].display_name | Intensive care medicine |
| concepts[4].id | https://openalex.org/C98274493 |
| concepts[4].level | 1 |
| concepts[4].score | 0.2680436670780182 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[4].display_name | Pharmacology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.15501800179481506 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9131555557250977 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/celecoxib |
| keywords[1].score | 0.7418601512908936 |
| keywords[1].display_name | Celecoxib |
| keywords[2].id | https://openalex.org/keywords/pharmacotherapy |
| keywords[2].score | 0.5742791295051575 |
| keywords[2].display_name | Pharmacotherapy |
| keywords[3].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[3].score | 0.5610045790672302 |
| keywords[3].display_name | Intensive care medicine |
| keywords[4].id | https://openalex.org/keywords/pharmacology |
| keywords[4].score | 0.2680436670780182 |
| keywords[4].display_name | Pharmacology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.15501800179481506 |
| keywords[5].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1007/s40265-025-02234-5 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4436492 |
| locations[0].source.issn | 0012-6667, 1179-1950 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0012-6667 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Drugs |
| locations[0].source.host_organization | https://openalex.org/P4310320330 |
| locations[0].source.host_organization_name | Adis, Springer Healthcare |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320330 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Drugs |
| locations[0].landing_page_url | https://doi.org/10.1007/s40265-025-02234-5 |
| locations[1].id | pmid:40911151 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Drugs |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40911151 |
| locations[2].id | pmh:oai:europepmc.org:11296500 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12484377 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5011109224 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-0827-5303 |
| authorships[0].author.display_name | Charlotte Beaudart |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I149768937 |
| authorships[0].affiliations[0].raw_affiliation_string | Public Health Aging Research & Epidemiology (PHARE) Group, Research Unit in Clinical, Pharmacology and Toxicology (URPC), NAmur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I149768937 |
| authorships[0].institutions[0].ror | https://ror.org/03d1maw17 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I149768937 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | University of Namur |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Charlotte Beaudart |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Public Health Aging Research & Epidemiology (PHARE) Group, Research Unit in Clinical, Pharmacology and Toxicology (URPC), NAmur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium |
| authorships[1].author.id | https://openalex.org/A5040096008 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Christian Brabant |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I157674565 |
| authorships[1].affiliations[0].raw_affiliation_string | Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium |
| authorships[1].institutions[0].id | https://openalex.org/I157674565 |
| authorships[1].institutions[0].ror | https://ror.org/00afp2z80 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I157674565 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | University of Liège |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Christian Brabant |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium |
| authorships[2].author.id | https://openalex.org/A5112212706 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-8147-3499 |
| authorships[2].author.display_name | Majed S. Alokail |
| authorships[2].countries | SA |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[2].affiliations[0].raw_affiliation_string | Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia |
| authorships[2].institutions[0].id | https://openalex.org/I28022161 |
| authorships[2].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[2].institutions[0].country_code | SA |
| authorships[2].institutions[0].display_name | King Saud University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Majed Alokail |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia |
| authorships[3].author.id | https://openalex.org/A5109971530 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Jean-Yves Reginster |
| authorships[3].countries | SA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[3].affiliations[0].raw_affiliation_string | Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia |
| authorships[3].institutions[0].id | https://openalex.org/I28022161 |
| authorships[3].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[3].institutions[0].country_code | SA |
| authorships[3].institutions[0].display_name | King Saud University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Jean-Yves Reginster |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia |
| authorships[4].author.id | https://openalex.org/A5014231492 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-4269-9393 |
| authorships[4].author.display_name | Olivier Bruyère |
| authorships[4].countries | BE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I157674565 |
| authorships[4].affiliations[0].raw_affiliation_string | Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium |
| authorships[4].institutions[0].id | https://openalex.org/I157674565 |
| authorships[4].institutions[0].ror | https://ror.org/00afp2z80 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I157674565 |
| authorships[4].institutions[0].country_code | BE |
| authorships[4].institutions[0].display_name | University of Liège |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Olivier Bruyère |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10678 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2736 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Inflammatory mediators and NSAID effects |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W364918769 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1007/s40265-025-02234-5 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4436492 |
| best_oa_location.source.issn | 0012-6667, 1179-1950 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0012-6667 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Drugs |
| best_oa_location.source.host_organization | https://openalex.org/P4310320330 |
| best_oa_location.source.host_organization_name | Adis, Springer Healthcare |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Drugs |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s40265-025-02234-5 |
| primary_location.id | doi:10.1007/s40265-025-02234-5 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4436492 |
| primary_location.source.issn | 0012-6667, 1179-1950 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0012-6667 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Drugs |
| primary_location.source.host_organization | https://openalex.org/P4310320330 |
| primary_location.source.host_organization_name | Adis, Springer Healthcare |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s40265-025-02234-5.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Drugs |
| primary_location.landing_page_url | https://doi.org/10.1007/s40265-025-02234-5 |
| publication_date | 2025-09-05 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3092849554, https://openalex.org/W2314408623, https://openalex.org/W4404971671, https://openalex.org/W4409205941, https://openalex.org/W3093461211, https://openalex.org/W2911328830, https://openalex.org/W4390974489, https://openalex.org/W2944136715, https://openalex.org/W2782392750, https://openalex.org/W2156098321, https://openalex.org/W2364450135, https://openalex.org/W2098995101, https://openalex.org/W3158355050, https://openalex.org/W2146160905, https://openalex.org/W2102526359, https://openalex.org/W4200248119, https://openalex.org/W2038114536, https://openalex.org/W2033527012, https://openalex.org/W2146447031, https://openalex.org/W1980256331, https://openalex.org/W2219147137, https://openalex.org/W2101592854, https://openalex.org/W2165039186, https://openalex.org/W1958389947, https://openalex.org/W2400280884, https://openalex.org/W2118840514, https://openalex.org/W2163756514, https://openalex.org/W4408529221, https://openalex.org/W2943119591, https://openalex.org/W2955666772, https://openalex.org/W4391957424, https://openalex.org/W2049656865, https://openalex.org/W1965992514, https://openalex.org/W2100631748, https://openalex.org/W2556825373, https://openalex.org/W2738243632, https://openalex.org/W2802155793, https://openalex.org/W2787676533, https://openalex.org/W1993961357, https://openalex.org/W4408350623, https://openalex.org/W4408117032, https://openalex.org/W3008540784, https://openalex.org/W4256513592 |
| referenced_works_count | 43 |
| abstract_inverted_index | |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5011109224 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 5 |
| corresponding_institution_ids | https://openalex.org/I149768937 |
| citation_normalized_percentile.value | 0.43079609 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |